MX344706B - Composición antigénica de micobacteria. - Google Patents

Composición antigénica de micobacteria.

Info

Publication number
MX344706B
MX344706B MX2013006818A MX2013006818A MX344706B MX 344706 B MX344706 B MX 344706B MX 2013006818 A MX2013006818 A MX 2013006818A MX 2013006818 A MX2013006818 A MX 2013006818A MX 344706 B MX344706 B MX 344706B
Authority
MX
Mexico
Prior art keywords
antigenic composition
mycobacterium
mycobacterium antigenic
composition
medicine
Prior art date
Application number
MX2013006818A
Other languages
English (en)
Other versions
MX2013006818A (es
Inventor
Ingrid Lemoine Dominique
Laanan Amina
Andre Georges Godart Stephane
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2013006818A publication Critical patent/MX2013006818A/es
Publication of MX344706B publication Critical patent/MX344706B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Abstract

La presente invención se refiere a composiciones inmunógenas que comprenden un antígeno relacionado con M72, en donde la conductividad de la composición es de 13 mS/cm o menor, o la concentración de sales de la composición es de 130 mM o menor, y su uso en medicina.
MX2013006818A 2010-12-14 2011-12-14 Composición antigénica de micobacteria. MX344706B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42272310P 2010-12-14 2010-12-14
PCT/EP2011/072816 WO2012080369A1 (en) 2010-12-14 2011-12-14 Mycobacterium antigenic composition

Publications (2)

Publication Number Publication Date
MX2013006818A MX2013006818A (es) 2013-08-26
MX344706B true MX344706B (es) 2017-01-03

Family

ID=45346501

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013006819A MX344280B (es) 2010-12-14 2011-12-14 Composicion antigenica de micobacteria.
MX2013006818A MX344706B (es) 2010-12-14 2011-12-14 Composición antigénica de micobacteria.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013006819A MX344280B (es) 2010-12-14 2011-12-14 Composicion antigenica de micobacteria.

Country Status (32)

Country Link
US (5) US9730992B2 (es)
EP (4) EP3593813A1 (es)
JP (2) JP5951634B2 (es)
KR (3) KR20140029376A (es)
CN (4) CN106822882A (es)
AR (1) AR084285A1 (es)
AU (2) AU2011343368C1 (es)
BR (2) BR112013014599A2 (es)
CA (2) CA2819298A1 (es)
CO (2) CO6751287A2 (es)
CY (1) CY1122187T1 (es)
DK (3) DK2651437T3 (es)
EA (2) EA027504B1 (es)
ES (3) ES2567190T3 (es)
HR (3) HRP20160362T1 (es)
HU (3) HUE045766T2 (es)
IL (2) IL226450A0 (es)
LT (1) LT3023106T (es)
ME (1) ME02380B (es)
MX (2) MX344280B (es)
MY (1) MY161412A (es)
PL (3) PL2651436T3 (es)
PT (2) PT2651436E (es)
RS (1) RS54687B1 (es)
SG (2) SG190731A1 (es)
SI (3) SI3023106T1 (es)
SM (1) SMT201600118B (es)
TW (1) TW201305192A (es)
UA (2) UA110806C2 (es)
UY (1) UY33802A (es)
WO (2) WO2012080369A1 (es)
ZA (2) ZA201304015B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5164830B2 (ja) 2005-04-29 2013-03-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 結核菌感染の予防または治療のための新規方法
MY161412A (en) 2010-12-14 2017-04-14 Glaxosmithkline Biologicals Sa Mycobacterium antigenic composition
HUE032409T2 (en) 2011-01-04 2017-09-28 Archivel Farma Sl Liposome preparation for treating or preventing tuberculosis
PT2802345T (pt) 2012-01-12 2018-04-24 Archivel Farma Sl Vacina mtb-c contra a asma
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CN113046312A (zh) 2014-04-23 2021-06-29 朱诺治疗学股份有限公司 分离、培养和遗传工程改造用于过继治疗的免疫细胞群的方法
GB201513176D0 (en) 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201522068D0 (en) * 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Dried composition
JP7136777B2 (ja) 2016-12-07 2022-09-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規プロセス
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600653B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
EP3717001A1 (en) 2017-12-01 2020-10-07 GlaxoSmithKline Biologicals S.A. Saponin purification
RU2728976C2 (ru) * 2018-03-22 2020-08-03 Зули Холдингз, Лтд. Липосомный состав и его получение
MX2021001129A (es) 2018-07-31 2021-07-02 Glaxosmithkline Biologicals Sa Metodo de purificacion de antigenos.
US20220339282A1 (en) 2018-11-29 2022-10-27 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
BR112021024363A2 (pt) 2019-06-05 2022-03-22 Glaxosmithkline Biologicals Sa Purificação de saponina
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
US20210069321A1 (en) 2019-09-09 2021-03-11 Glaxosmithkline Biologicals Sa Immunotherapeutic compositions
CA3161857A1 (en) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
MX2022013855A (es) 2020-05-05 2022-11-30 Glaxosmithkline Biologicals Sa Dispositivos de mezcla de microfluidos y metodos de uso.
US20230234992A1 (en) 2020-06-05 2023-07-27 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
WO2022122830A2 (en) 2020-12-09 2022-06-16 Glaxosmithkline Biologicals Sa Saponins
CN114034860A (zh) * 2021-11-01 2022-02-11 宁夏大学 一种结核分枝杆菌mtb39a蛋白抗体间接elisa检测方法及其试剂盒
WO2023242187A1 (en) 2022-06-15 2023-12-21 Glaxosmithkline Biologicals Sa Enzymatic modification of saponins
CN116120411B (zh) * 2022-12-07 2024-04-12 中国疾病预防控制中心传染病预防控制所 结核分枝杆菌蛋白抗原混合物、多抗原融合蛋白及编码基因和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DK0382271T3 (da) 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoler som adjuvanser i vacciner
DE69405551T3 (de) 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
IL123506A (en) 1995-09-01 2004-12-15 Corixa Corp Polypeptide compounds and preparations for immunotherapy and diagnosis of tuberculosis
ATE324445T1 (de) 1995-09-01 2006-05-15 Corixa Corp Verbindungen und verfahren zur diagnose von tuberkulose
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
GB9619613D0 (en) 1996-09-19 1996-10-30 Breed Automotive Tech An inflatable restraint for a vehicle
EP0859366A1 (en) 1997-02-12 1998-08-19 STMicroelectronics S.r.l. Associative memory device with optimized occupation, particularly for the recognition of words
KR20010006169A (ko) * 1997-04-08 2001-01-26 폴락 돈나 엘. 안정화된 사람 파필로마바이러스 제형물
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
AU753995B2 (en) 1998-04-07 2002-10-31 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
WO1999052549A1 (en) * 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
WO2001024820A1 (en) 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
ATE442866T1 (de) 2000-06-20 2009-10-15 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
AU8189501A (en) 2000-06-29 2002-01-08 Smithkline Beecham Biolog Vaccine composition
US7026465B2 (en) 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
JP5164830B2 (ja) * 2005-04-29 2013-03-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 結核菌感染の予防または治療のための新規方法
EP2368568A1 (en) 2006-11-01 2011-09-28 Immport Therapeutics, INC. Compositions and methods for immunodominant antigens
CA2687632C (en) 2007-05-24 2013-01-15 Glaxosmithkline Biologicals S.A. Lyophilised antigen composition
CA2707483A1 (en) 2007-11-30 2009-06-11 Wolfgang Fraunhofer Protein formulations and methods of making same
KR100955470B1 (ko) * 2008-01-09 2010-04-30 대한민국(관리부서 질병관리본부장) 탄저 방어 항원의 제조 방법
US8409901B2 (en) 2008-03-11 2013-04-02 The Royal Institution For The Advancement Of Learning/Mcgill University Low temperature wafer level processing for MEMS devices
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB201008512D0 (en) 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
IT1400834B1 (it) 2010-07-07 2013-07-02 Aero Sekur S P A Metodo e sistema per l'atterraggio di emergenza di un veicolo, come un elicottero o simili.
MY161412A (en) 2010-12-14 2017-04-14 Glaxosmithkline Biologicals Sa Mycobacterium antigenic composition
GB201400819D0 (en) 2014-01-17 2014-03-05 Sec Dep For Health The Mycobacterial antigen composition

Also Published As

Publication number Publication date
EA201390631A1 (ru) 2014-11-28
EP3593813A1 (en) 2020-01-15
PT3023106T (pt) 2019-11-04
US20130287809A1 (en) 2013-10-31
KR20190022897A (ko) 2019-03-06
AU2011343367A1 (en) 2013-07-11
SI2651437T1 (sl) 2016-05-31
SI3023106T1 (sl) 2019-11-29
CO6751288A2 (es) 2013-09-16
CA2819298A1 (en) 2012-06-21
US9730992B2 (en) 2017-08-15
US20190183998A1 (en) 2019-06-20
UA110806C2 (uk) 2016-02-25
JP2013545783A (ja) 2013-12-26
KR101951894B1 (ko) 2019-02-26
PL3023106T3 (pl) 2019-12-31
CO6751287A2 (es) 2013-09-16
EA201390630A1 (ru) 2013-12-30
KR20130124525A (ko) 2013-11-14
HRP20191843T1 (hr) 2019-12-27
UA110118C2 (uk) 2015-11-25
IL226448A0 (en) 2013-07-31
EP2651437A1 (en) 2013-10-23
SMT201600118B (it) 2016-07-01
MX2013006818A (es) 2013-08-26
AU2011343368C1 (en) 2015-12-24
RS54687B1 (en) 2016-08-31
CN103260642B (zh) 2018-03-16
CN103249431A (zh) 2013-08-14
ES2574403T3 (es) 2016-06-17
JP2014505036A (ja) 2014-02-27
SG190731A1 (en) 2013-07-31
EA027504B1 (ru) 2017-08-31
MY161412A (en) 2017-04-14
WO2012080369A1 (en) 2012-06-21
ME02380B (me) 2016-06-20
US10441648B2 (en) 2019-10-15
ZA201304014B (en) 2017-04-26
EP2651436A1 (en) 2013-10-23
EP2651437B1 (en) 2016-02-10
EP3023106B1 (en) 2019-07-31
ZA201304015B (en) 2018-12-19
CN106822883A (zh) 2017-06-13
AU2011343368A1 (en) 2013-07-11
SI2651436T1 (sl) 2016-07-29
JP5951634B2 (ja) 2016-07-13
ES2748651T3 (es) 2020-03-17
LT3023106T (lt) 2019-10-25
CA2819297A1 (en) 2012-06-21
PL2651437T3 (pl) 2016-07-29
DK2651437T3 (en) 2016-05-02
UY33802A (es) 2012-07-31
HUE027932T2 (en) 2016-11-28
BR112013014599A2 (pt) 2016-09-27
ES2567190T3 (es) 2016-04-20
IL226450A0 (en) 2013-07-31
PL2651436T3 (pl) 2016-10-31
PT2651436E (pt) 2016-06-08
AU2011343368B2 (en) 2015-08-20
DK3023106T3 (da) 2019-09-30
US20130280289A1 (en) 2013-10-24
IL226448A (en) 2017-09-28
MX2013006819A (es) 2013-08-26
US20160220656A1 (en) 2016-08-04
CY1122187T1 (el) 2020-11-25
JP5951633B2 (ja) 2016-07-13
MX344280B (es) 2016-12-09
EP3023106A1 (en) 2016-05-25
HRP20160362T1 (hr) 2016-05-06
HUE045766T2 (hu) 2020-01-28
CN103249431B (zh) 2016-11-02
US20180071378A1 (en) 2018-03-15
AU2011343367B2 (en) 2015-05-21
SG190937A1 (en) 2013-07-31
EP2651436B1 (en) 2016-03-30
AR084285A1 (es) 2013-05-08
CN106822882A (zh) 2017-06-13
TW201305192A (zh) 2013-02-01
DK2651436T3 (da) 2016-06-20
WO2012080370A1 (en) 2012-06-21
BR112013014598A2 (pt) 2017-09-19
KR20140029376A (ko) 2014-03-10
CN103260642A (zh) 2013-08-21
HUE028452T2 (en) 2016-12-28
EA027920B1 (ru) 2017-09-29
HRP20160606T1 (hr) 2016-07-01
US9352030B2 (en) 2016-05-31

Similar Documents

Publication Publication Date Title
MY161412A (en) Mycobacterium antigenic composition
NZ606589A (en) 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
PH12014501836A1 (en) Novel adjuvant compositions
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
MX2013003282A (es) Materiales y metodos para mejorar la funcion gastrointestinal.
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
MX2013003162A (es) Composicion farmaceutica.
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
GB201106750D0 (en) Novel compounds
MX2013004123A (es) Composiciones antitusigenas que comprenden memantina.
TR201802380T4 (tr) Benzonaftiridin içeren aşılar.
MX2015003352A (es) Extracto de saliva entera de sanguijuela.
EA201500054A1 (ru) Аттенуированные вакцины против streptococcus suis и способы их получения и применения
EA201190285A1 (ru) Иммуногенные композиции, имеющие низкую концентрацию хлорида натрия
MX2012007970A (es) Proceso para la preparacion de una biomasa que comprende plantaricina y usos de la misma en el campo medico.
BR112015020079A2 (pt) composições para cuidado oral
BR112014013327A2 (pt) composições para cuidado oral
CO7151515A2 (es) Métodos para tratar deficiencia en la marcha y/o equilibrio en pacientes con esclerosis múltiple que utilizan una aminopiridina
MX2013012551A (es) Uso de sales de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio en el tratamiento de enfermedades cardiovasculares.
CY1117640T1 (el) Αντιγονικη συνθεση μυκοβακτηριου
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
Prilipko et al. Analiz raboty reabilitatsionnykh meditsinskikh uchrezhdeniy zdravookhraneniya Rossiyskoy Federatsii
TN2013000404A1 (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
GB201106340D0 (en) Composition
UA70225U (ru) Применение композиции, содержащей мирамистин, в качестве лекарственного средства для лечения заболеваний горла

Legal Events

Date Code Title Description
FG Grant or registration